Technology/ Title

DCBPR1702: A Therapeutic TIM-3 antibody in preclinical studies for treatment of Hepatocellular Carcinoma (HCC)

Technology Type





Contact Person

Name: Joseph Liu

Title: Project Manager

Telephone(work): +886-02-7700-3800  ext. 5237


2019 BioAsia





Technology Description


  • Summary of Invention:

T cell immunoglobulin and mucin domain-3 (TIM-3), also known as hepatitis A virus cellular receptor 2 (HAVCR2), is a cell surface molecule expressed on CD4+ Th1, CD8+ cytotoxic T cells, Th17 cells, Treg cells and other innate immune cells. TIM-3 acts as a co-inhibitory receptor with programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG-1). TIM-3 is primarily activated by galectin-9 (Gal-9). The Gal-9/Tim-3 signal leads to programmed cell death, apoptosis. DCBPR1702 is an anti-human TIM-3 monoclonal antibody, generated by hybridoma technology and followed by humanization. DCBPR1702 is produced in mammalian cell lines for further pre-clinical development. DCBPR1702 had shown high affinity and specificity to human TIM-3 in ELISA and BIAcore experiments. Human T cells treated with DCBPR1702 had significantly enhanced the cytokine secretion. DCBPR1702 can block (compete with) the binding of TIM-3 with Gal-9. It also can block the binding of Gal-9 to human CD4 T cells and reduce T cell apoptosis. In vitro and in vivo anti-tumor activity of DCBPR1702 had been examined along or with anti-PD-1 monoclonal antibody. 

  • Conclusions: The results demonstrate DCBPR1702 is a TIM-3 antibody with potent dose-dependent TGI, which supports its further preclinical drug development.
  • Advantages when compared to the existing technologies:
  1. DCBPR1702 inhibits TIM-3/Gal-9 binding, prevents T cell apoptosis and increases anti-tumor activity in vivo.
  2. Combined with anti-PD-1 shows promising results.
  3. US Patents have been filed. First patented antibody that inhibits TIM-3/Gal-9 binding.

Intellectual Property

US provisional and US patent applied

Business Opportunity

Immune-oncology cancer therapy




1. 針對人類T細胞上的TIM-3結合,具有相當高的專一性與親和力(Kd~10-11 M);
2. 可刺激T細胞分泌相關毒殺型T細胞所需的細胞激素;
3. 在小鼠腫瘤模式下隨著藥物劑量增加呈現抑制腫瘤成長的能力;
4. 所應用的癌症免疫治療機制,具有與一般的小/大分子藥物合併治療的商業潛力。






聯絡人: 鍾牧樺
TEL:  (02)7700-3800 #5235